MarketBeat
26 May 2026, 23:04 UTC · 24w ago
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
Verdict
Headline leans bullish. We score IDYA +0.90 across five claims.
Score confirms the headline.
- Headline says
Leans bullish
From its wording — no explicit rating
- Expected · IDYA
+0.90strongly bullish





